VENORUTON CAPSULES 300MG

Venoruton - venotonic and angioprotective drug. It helps to strengthen the walls of capillaries, normalizes their permeability, improves microcirculation. Reduces the severity of symptoms of chronic venous insufficiency (edema, convulsions, paresthesia, trophic disorders), hemorrhoids (pain, exudation); some phenomena that occur during radiation therapy. It helps to slow down the development of retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.

Mechanism of action

 
Venoruton is a drug with venotonic and angioprotective effects for ingestion and external use. Affects mainly capillaries and veins.
Venoruton has a protective effect on the vascular endothelium. It helps to strengthen the walls of capillaries and normalize their permeability. Prevents the opening of the intercellular gaps and a sharp increase in hydroconductivity, induced by platelets and neutrophils. It reduces the pores between endothelial cells by modifying the fibrous matrix located between the endothelium cells. It has a protective effect even when the endothelial barrier is already broken and restores the disturbed morphological properties and endothelial hydroconductivity.
Venoruton has anti-inflammatory effects.Inhibits activation and adhesion of neutrophils, reduces the release of inflammatory mediators.
Venoruton reduces the aggregation of erythrocytes, increases the resistance of erythrocytes to deformation.
Venoruton prevents damage to the cell membranes caused by oxidation. The antioxidant effect is manifested in reducing the oxidative properties of oxygen, inhibiting lipid peroxidation, protecting the vascular endothelium from the oxidative action of hydroxyl radicals and hypochlorous acid.
Venoruton increases venous arterial reflux, prolongs the time of venous filling, reduces blood flow to the skin (lying), improves microcirculation and microvascular perfusion.
In chronic venous insufficiency, Venoruton reduces the severity of its manifestations such as edema, pain, convulsions, trophic disorders, varicose dermatitis, and varicose ulcers.
Venoruton relieves the symptoms commonly associated with hemorrhoids - pain, exudation, itching, and bleeding.
Venoruton reduces the severity of certain phenomena that occur during radiation therapy and are in some cases the reason for its cancellation. These are such phenomena as cystitis, enteroproctitis, dysphagia, redness of the skin, etc.
Due to the favorable effect of Venoruton on the permeability and resistance of the capillary walls, it helps to slow down the development of diabetic retinopathy.In addition, the influence of Venorouton on the rheological properties of blood contributes to the prevention of microthrombosis and other retinal lesions of vascular genesis.
Venoruton gel reduces swelling, as well as the severity of other symptoms associated with chronic venous insufficiency of the lower extremities or traumatic injury. Venoruton gel is a water-based gel that does not contain alcohol; it is easily absorbed, odorless and does not leave greasy stains.

Pharmacokinetics

After oral administration, the absorption of oxerutin (14C-0- (b-hydroxyethyl) -rustozidov / is about 10-15%. The maximum concentration (Cmax) in plasma is achieved within 1-9 hours. For 120 hours, the oxerutin concentration remains detectable; its decrease occurs biexponentially. The half-life (T1 / 2) varies from 10 to 25 hours. It is excreted unchanged and in the form of glucuronized metabolites mainly with bile; 3-6% excreted by the kidneys within 48 hours.
When applied topically, oxerutin penetrates rapidly through the epidermis; after 30 minutes it is found in the dermis; after 2-5 hours - in the subcutaneous fatty tissue. When applied topically, all available methods for determining the blood concentration of the active substance are not sensitive enough.

Indications and usage

Venoruton for oral administration:

• swelling and symptoms (fatigue, heaviness and pain in the legs, cramps, paresthesias) associated with chronic venous insufficiency;
• post-phlebitic syndrome;
• trophic disorders in varicose veins, varicose dermatitis, varicose ulcers;
• lymphostasis and pain after sclerotherapy and the removal of varicose nodes (as an auxiliary treatment);
• symptoms of hemorrhoids (pain, exudation, itching and bleeding) and their complications;
• venous insufficiency and hemorrhoids during pregnancy, starting from the 4th month (from the second trimester);

• reactions to radiation therapy from the vessels and mucous membranes (prevention and treatment);
• retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis (as an auxiliary treatment);
• prevention of episodes of transient blindness.

• symptoms associated with chronic venous insufficiency of the lower extremities (pain, feeling of heaviness in the legs, swelling of the ankles);
• pain after sclerotherapy;
• pain and swelling of traumatic genesis, incl. damage (sprains, bruises) ligaments or muscles.

 
Venoruton for oral administration:

Chronic venous insufficiency, varicose veins, hemorrhoids. At the initial stage of treatment, Venoruton is prescribed 300 mg (1 capsule) 3 times a day, or 500 mg (1 pill forte) 2 times a day, or 1000 mg (1 effervescent tablet) 1 time per day; while eating. Reducing symptoms is usually noted within 2 weeks of treatment. It is recommended to continue taking Venoruton in the same dose until the complete disappearance of edema and other symptoms. Then treatment with Venoruton can be interrupted.Improvement usually lasts at least 4 weeks after discontinuation of treatment. When symptoms resume, treatment with Venoruton should be restarted, either with the above doses or with maintenance doses. Maintenance Treatment: The minimum maintenance dose of Venoruton is 600 mg per day, i.e. 300 mg (1 capsule) 2 times a day.

Lymphostasis and pain after sclerotherapy and removal of varicose nodes. The recommended dose of Venoruton is 3 g per day - 1000 mg (2 pills forte or 1 effervescent tablet) 3 times per day.

Radiation therapy. In order to prevent and treat the side effects of radiation therapy, Venoruton is prescribed 500 mg (1 pill forte) per day with meals. Treatment should continue in the course of radiotherapy and up to the complete disappearance of symptoms.

Retinopathy. For the treatment of pathological changes in retinal vessels, doses of 1-2 g per day are successfully applied, i.e. 500-1000 mg (1-2 pills forte or 1 effervescent tablet) 2 times a day.

Venoruton Gel (for external use): 

The gel is applied to the affected area 2 times a day, morning and evening, gently rubbing until completely absorbed. If necessary Venoruton gel can be applied under bandages or elastic stockings. Maintenance dose - 1 time per day for the night.

Overdosage

No cases of overdose of Venoruton, which would be accompanied by clinical manifestations, were reported.

Contraindications

• hypersensitivity to rutosides;
• I trimester of pregnancy.

Pregnancy and breastfeeding

In clinical studies, the use of Venoruton during pregnancy was studied, but its use in the first trimester has not been specifically studied. In studies conducted in animals, no teratogenic or any other undesirable effects on the fetus were noted. Taking into account all the above, as well as guided by the rules adopted in clinical practice, the appointment of Venoruton inside is recommended only from the 4th month (from the second trimester) of pregnancy and only with absolute indications. Traces of ruthoside detected in fetal tissues and breast milk (experimental animal studies) are not considered clinically significant.
There is no need to observe special precautions when prescribing Venoruton in the form of a gel in the II and III trimesters of pregnancy or during lactation.

On the part of the digestive system: if taken orally, mild dyspeptic disorders (nausea, diarrhea, heartburn) are possible.
Allergic reactions: rarely - skin rash (when taken orally or externally).
Other: for ingestion - possible headaches, flushing of the face.
Side effects disappear quickly after stopping the use of Venoruton.

If during the period of application of Venoruton, the severity of symptoms of the disease does not decrease, you should consult with your doctor.

The action of Venoruton is enhanced while taking Ascorbic acid .
Data on other drug interactions of Venoruton are not available.

Store in a dry place out of the reach of children, at room temperature (not exceeding 30 ° C).